Bavarian Nordic A/S (CPH:BAVA)
Denmark · Delayed Price · Currency is DKK 228.00
+0.10 (0.04%)
Sep 29, 2025, 2:57 PM CET
Bavarian Nordic Revenue
Bavarian Nordic had revenue of 1.65B DKK in the quarter ending June 30, 2025, with 15.69% growth. This brings the company's revenue in the last twelve months to 6.46B, up 6.13% year-over-year. In the year 2024, Bavarian Nordic had annual revenue of 5.72B, down -19.06%.
Revenue (ttm)
6.46B
Revenue Growth
+6.13%
P/S Ratio
2.76
Revenue / Employee
3.87M
Employees
1,605
Market Cap
17.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.72B | -1.35B | -19.06% |
| Dec 31, 2023 | 7.06B | 3.91B | 124.14% |
| Dec 31, 2022 | 3.15B | 1.25B | 66.02% |
| Dec 31, 2021 | 1.90B | 45.49M | 2.46% |
| Dec 31, 2020 | 1.85B | 1.19B | 179.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 311.94B |
| Coloplast | 27.87B |
| Genmab | 23.16B |
| Demant | 22.59B |
| ALK-Abelló | 5.86B |
| H. Lundbeck | 23.52B |
| Zealand Pharma | 9.11B |
| Ambu A/S | 5.96B |
Bavarian Nordic News
- 24 days ago - Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise - GlobeNewsWire
- 4 weeks ago - Publication of statement by the Board of Directors in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira - GlobeNewsWire
- 4 weeks ago - Publication of offer document in respect of the takeover offer to the shareholders of Bavarian Nordic from the consortium led by Nordic Capital and Permira and lowering of minimum acceptance condition to 75% - GlobeNewsWire
- 5 weeks ago - Bavarian Nordic AS (BVNKF) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... - GuruFocus
- 5 weeks ago - Bavarian Nordic A/S 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Bavarian Nordic A/S (BVNKF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Bavarian Nordic beats revenue expectations, as launch of takeover bid nears - Reuters
- 5 weeks ago - Bavarian Nordic (BVNKF) Reports Strong Revenue Growth in 1H 2024 - GuruFocus